Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANB-033 (Primary) ; ANB-033 (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio

Most Recent Events

  • 12 Oct 2026 According to a First Tracks Biotherapeutics media release, cohort 2 of the phase 1b celiac disease trial is evaluating mucosal healing over 12 weeks, with topline results anticipated in Q1 2027. A Phase 1b cohort evaluating ANB033 in eosinophilic esophagitis (EoE) is enrolling 50 patients, with topline data anticipated in Q3 2027
  • 12 Oct 2026 Results presented in a First Tracks Biotherapeutics media release
  • 12 Oct 2026 According to a First Tracks Biotherapeutics media release, company announced positive topline results from Cohort 1 (gluten challenge) of the Phase 1b clinical trial evaluating ANB033 in patients with celiac disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top